Patent ID: 7837992
Filing Date: 2010-11-23
Classification: A61K,A61P,C12Y

Abstract:
1. A method of accelerating the rate of blood clot lysis while preventing fibrinogen degradation in a human patient, comprising: a) providing M5 and exogenous C1-inhibitor; b) administering to a human patient an amount of M5 sufficient to establish M5 concentrations of 10-15 μg/ml in the plasma of the patient; and c) administering, at the same time or before step b), an amount of exogenous C1-inhibitor sufficient to establish a concentration of C1-inhibitor, in the plasma of the patient, that is within the range of 1.5 to 4 times average normal physiological levels; wherein non-specific plasminogen activation by M5 is prevented.